FLT3 mutational analysis in acute myeloid leukemia: Advantages and pitfalls with different approaches. (July 2022)

• Record Type: Journal Article
• Authors: Cumbo, Cosimo; Tarantini, Francesco; Anelli, Luisa; Zagaria, Antonella; Specchia, Giorgina; Musto, Pellegrino; Albano, Francesco
• Is Part Of: Blood reviews. Volume 54(2022)
• Publication Date: 2022-07
• Subjects: FLT3 mutational analysis -- Acute myeloid leukemia -- Fragment analysis -- Next-generation sequencing; Hematology -- Periodicals; Hematology -- Periodicals; Hématologie -- Périodiques; Hematology; Electronic journals; Periodicals; 616.15
• DOI: 10.1016/j.blre.2022.100928
• Languages: English
• ISSNs: 0268-960X

Abstract

Abstract: FMS-like tyrosine kinase 3 ( FLT3 ) is one of the most closely studied genes in blood diseases. Numerous methods have been adopted for analyses, mainly in acute myeloid leukemia (AML) diagnostic work-up. According to international recommendations, the current gold standard approach allows FLT3 canonical mutations to be investigated, providing the main information for risk assessment and treatment choice. However, the technological improvements of the last decade have permitted "black side" gene exploration, revealing numerous hidden aspects of its role in leukemogenesis. The advent of the next-generation sequencing era emphasizes lights and shadows of FLT3 conventional mutational analysis, highlighting the need for a more comprehensive study of the gene. However, more extensive analysis is opening new, unexplored questions whose impact on clinical outcomes is still unknown. The present work is focused on the main topics regarding FLT3 mutational analysis in AML, debating the strengths and weaknesses of the current gold standard approach. The rights and wrongs of NGS introduction in clinical practice will be discussed, showing that a more extensive knowledge of FLT3 mutational status could lead to reconsidering its role in AML management.